bpc-157 fda approved 2025 advisory committee votes to add popular peptide to drug compounding list Wolverine Stack: Healing Faster with

doi: 10.1016/j.ijpharm.2008.08.042

Their strong recommendations apply to procedures such as epidural steroid injections and nerve blocks for people living with chronic back pain (lasting at least 3 months) that is not associated with cancer, infection or inflammatory arthritis

Safety concerns included uncharacterized immunogenicity (the risk that injected peptides trigger immune reactions), inadequate impurity and endotoxin testing in available raw material, the unresolved free base versus acetate salt form distinction, and, for BPC-157 specifically, an angiogenesis mechanism that raises theoretical cancer-risk concerns for certain patient populations

The FDA document was updated May 14, 2026 to reflect the reversal and to flag that the agency will consult the Pharmacy Compounding Advisory Committee, or PCAC, before the end of February 2027 about whether GHK-Cu should be added to the permanent 503A bulks list